PatentJul 14, 2026, 07:03 AM
Can-Fite BioPharma Secures Australian Patent for Advanced Metastatic Cancer Treatment
AI Summary
Can-Fite BioPharma Ltd. announced that the Australian Patent Office has allowed its patent application for "Treatment of Advanced Metastatic Cancer." This patent significantly strengthens the company's global intellectual property portfolio surrounding its lead drug candidate, Namodenoson. The allowance specifically supports Namodenoson's advanced oncology programs, including its pivotal Phase 3 study for hepatocellular carcinoma and its promising Phase 2a results in pancreatic cancer, with a Phase 2b study planned.
Key Highlights
- Australian Patent Office allowed Patent Application No. 2021290439 for "Treatment of Advanced Metastatic Cancer."
- The patent strengthens Can-Fite's global intellectual property portfolio for Namodenoson.
- It supports Namodenoson's oncology programs in hepatocellular carcinoma (HCC) and pancreatic cancer.
- Namodenoson is currently in a pivotal Phase 3 study for advanced hepatocellular carcinoma.
- Namodenoson completed a Phase 2a study in pancreatic cancer and is planning a Phase 2b study.
- Namodenoson selectively targets the A3 adenosine receptor (A3AR), inducing apoptosis of tumor cells.
Price Impact
More from CANF